Beta Blockers for Atrial Fibrillation Rate Control

First-Line Beta Blockers for A-Fib

The American College of Cardiology recommends metoprolol as a first-line beta blocker for A-Fib rate control, with dosing of 25-100 mg twice daily orally for chronic maintenance therapy 1
The American College of Cardiology suggests propranolol is equally effective for rate control, typically dosed at 80-240 mg daily in divided doses 1
Esmolol is preferred for acute settings requiring rapid rate control, administered as 500 mcg/kg IV over 1 minute, followed by 60-200 mcg/kg/min IV, according to the American College of Cardiology 1

The American College of Cardiology recommends intravenous digoxin or amiodarone to control heart rate in patients with A-Fib and heart failure 2
For chronic management in heart failure patients, the American College of Cardiology indicates digoxin (0.125-0.375 mg daily) 1
Oral amiodarone may be considered when heart rate cannot be adequately controlled with other agents in heart failure patients, as suggested by the American College of Cardiology 2, 3 is replaced with:
Oral amiodarone may be considered when heart rate cannot be adequately controlled with other agents in heart failure patients, according to the American College of Cardiology 2

The European Society of Cardiology suggests beta-1 selective blockers (e.g., bisoprolol) in small doses for ventricular rate control in patients with obstructive pulmonary disease 4
Non-selective beta-blockers, sotalol, propafenone, and adenosine are contraindicated in patients with obstructive lung disease, as stated by the European Society of Cardiology 4
Non-dihydropyridine calcium channel antagonists (diltiazem or verapamil) are preferred for rate control in patients with bronchospastic lung disease, according to the European Society of Cardiology 4

A combination of digoxin and either a beta blocker or non-dihydropyridine calcium channel antagonist is reasonable to control heart rate both at rest and during exercise, as recommended by the American College of Cardiology 2, 5 is replaced with:
A combination of digoxin and either a beta blocker or non-dihydropyridine calcium channel antagonist is reasonable to control heart rate both at rest and during exercise, according to the American College of Cardiology 2
The choice of medication should be individualized and the dose carefully titrated to avoid bradycardia, as suggested by the American College of Cardiology 5
Adequacy of heart rate control should be assessed during physical activity as well as at rest, according to the American College of Cardiology 1

For acute rate control, intravenous beta blockers (esmolol, metoprolol, or propranolol) or non-dihydropyridine calcium channel antagonists (verapamil, diltiazem) are recommended by the American College of Cardiology 2
Exercise caution in patients with hypotension or heart failure when administering these agents, as advised by the American College of Cardiology 2
Intravenous amiodarone can be useful when other measures are unsuccessful or contraindicated, according to the American College of Cardiology 2

Non-dihydropyridine calcium channel blockers should be avoided in patients with reduced ejection fraction due to their negative inotropic effects, however this fact is from Praxis Medical Insights and is replaced with no fact.

The American College of Cardiology recommends esmolol as the preferred beta blocker drip for treating atrial fibrillation, administered as a 500 mcg/kg IV loading dose over 1 minute, followed by a continuous infusion of 60-200 mcg/kg/min 6
Esmolol offers distinct advantages as an ultra-short-acting agent with rapid onset and offset, making it particularly useful when titration flexibility is needed or in hemodynamically unstable situations 6

Beta blockers are particularly effective in states of elevated sympathetic tone, including postoperative atrial fibrillation, as recommended by the American College of Cardiology and the European Heart Society 6, 7
In patients with heart failure and LVEF ≤40%, beta blockers remain recommended but require careful dosing, according to the European Heart Society 8
Beta blockers and/or digoxin are first-line for rate control in heart failure patients with AF, as suggested by the European Heart Society 8

Beta blockers are absolutely contraindicated in AF with Wolff-Parkinson-White syndrome, as they may paradoxically accelerate ventricular rate and precipitate ventricular fibrillation, according to the European Heart Society 7
When hemodynamically unstable, proceed directly to electrical cardioversion, as recommended by the European Heart Society 7
Exercise caution with all negative chronotropic agents in decompensated heart failure, as suggested by the American College of Cardiology 9

Assess adequacy of rate control during both rest and exercise, adjusting doses to maintain physiologic range, as recommended by the American College of Cardiology 9
Reduce or discontinue infusion if hypotension, bradycardia, or cardiac failure develops, although this is not directly cited, it is implied by the context of beta blocker therapy
Combination of digoxin with either a beta blocker or non-dihydropyridine calcium channel antagonist provides superior rate control at rest and during exercise, as suggested by the American College of Cardiology 9
Carefully titrate doses to avoid excessive bradycardia, as recommended by the American College of Cardiology 9